Collectively, these studies establish EDA2R as a central mediator of muscle wasting in both sarcopenia and cachexia and highlight its potential as a therapeutic target to mitigate muscle degeneration associated with ageing and chronic illness. Here, EDA2R is linked to sarcopenia.